Table 2.
Clinical data and ipilimumab treatment results of 70 patients with AJCC stage IV melanoma who received or did not receive melanoma vaccine.
| Prior vaccination | Yes | No | p ∗ | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Patient number | 35 | 50 | 35 | 50 | |
| M stage | |||||
| M1A | 8 | 23 | 3 | 9 | 0.3 |
| M1B | 8 | 23 | 10 | 28 | |
| M1C | 19 | 54 | 22 | 63 | |
| Dose | |||||
| 3 mg/kg | 30 | 86 | 32 | 91 | 0.45 |
| 10 mg/kg | 5 | 14 | 3 | 9 | |
| Reinduction | 4 | 12 | 3 | 9 | |
| Treatment stopped for toxicity | 5 | 14 | 2 | 6 | |
| Objective response | |||||
| CR | 3 | 9 | 3 | 9 | 0.03 ∗∗ |
| PR | 10 | 29 | 4 | 11 | |
| S | 6 | 17 | 1 | 3 | |
| P | 16 | 46 | 27 | 77 | |
| Survival data | |||||
| Median OS (months) | 31 (3–47) | 9 (2–50) | 0.007 | ||
| 3-year survival rate | 46% | 19% | |||
CR: complete response, PR: partial response, S: stable disease, and P: progression.
∗Pearson chi square (two-sided) test.
∗∗ p value for progression (P) versus any benefit (CR, PR, and S).